The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection
Abstract
The efficacy of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection was assessed in 16 patients with functional or anatomical abnormalities of the urinary tract. Depending on renal function the dosage varied from 100 mg once daily to 250 mg twice daily. All patients were treated for 14 days. Bacteriological cure was documented for seven patients (44%) during the 8 week follow-up period. In a further seven patients the urine was sterile during treatment but relapse occurred within four weeks of completing the course. Persistence was noted in two cases, one of which was associated with the development of resistance. No significant adverse reactions were recorded. Chronic P. aeruginosa infection of the abnormal urinary tract can be very difficult to eradicate and ciprofloxacin may offer a valuable alternative to potentially more toxic parenteral agents.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.